Enveric Biosciences, Inc. (NASDAQ:ENVB) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) with Series I and short-term Series J warrants Closed: US$5M raised · US$2.25 a share · Warrants at US$2 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Apr 17, 2026 |
| Registered direct offering of shares of common stock with unregistered series G and series H warrants Closed: US$1.5M raised · US$4.41 a share · Warrants at US$4.16 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Jan 28, 2026 |
| Warrant exercise of outstanding warrants exercised for common stock Closed: US$3.1M raised · US$7.05 a share · Warrants at US$7.05 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Dec 12, 2025 |
| Warrant exercise of series A and series B warrants exercised for common stock Closed: US$2.2M raised · US$0.915 a share · Warrants at US$0.915 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Sep 18, 2025 |
| Public offering of common stock (or common stock equivalents) with Series A and Series B warrants Closed: US$5M raised · US$3 a share · Warrants at US$3 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Feb 3, 2025 |